Evidence map›Paper›PMID 42760303›Full record

ArticleBritish journal of cancer2026

Genomic and transcriptomic landscape of spread through air spaces in stage 1 lung adenocarcinoma.

Stephanie P L Saw, Mengyuan Pang, Clare Patteri, Angela Takano, Jia Chi Yeo, Ngak Leng Sim, Gillianne G Y Lai, Darren W T Lim, Mei-Kim Ang, Ravindran Kanesvaran and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Stephanie P L SawDivision of Medical Oncology, National Cancer Centre, Singapore, Singapore. stephanie.saw.p.l@singhealth.com.sg.ORCID http://orcid.org/0000-0003-3520-9464
Mengyuan PangGenome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Clare PatteriDivision of Medical Oncology, National Cancer Centre, Singapore, Singapore.
Angela TakanoDepartment of Pathology, Singapore General Hospital, Singapore, Singapore.
Jia Chi YeoGenome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Ngak Leng SimGenome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Gillianne G Y LaiDivision of Medical Oncology, National Cancer Centre, Singapore, Singapore.
Darren W T LimDivision of Medical Oncology, National Cancer Centre, Singapore, Singapore.ORCID http://orcid.org/0000-0002-4655-0206
Mei-Kim AngDivision of Medical Oncology, National Cancer Centre, Singapore, Singapore.
Ravindran KanesvaranDivision of Medical Oncology, National Cancer Centre, Singapore, Singapore.
Quan Sing NgDivision of Medical Oncology, National Cancer Centre, Singapore, Singapore.
Amit JainDivision of Medical Oncology, National Cancer Centre, Singapore, Singapore.
Wan Ling TanDivision of Medical Oncology, National Cancer Centre, Singapore, Singapore.
Aaron C TanDivision of Medical Oncology, National Cancer Centre, Singapore, Singapore.
Wei Chong TanDivision of Medical Oncology, National Cancer Centre, Singapore, Singapore.
Amanda O L SeetDivision of Medical Oncology, National Cancer Centre, Singapore, Singapore.
Boon-Hean OngDepartment of Cardiothoracic Surgery, National Heart Centre, Singapore, Singapore.
Tony K H LimDepartment of Pathology, Singapore General Hospital, Singapore, Singapore.
Anders Jacobsen SkanderupGenome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Daniel S W TanDivision of Medical Oncology, National Cancer Centre, Singapore, Singapore.

Funding

MOH | National Medical Research Council (NMRC) NMRC/MOH-TA24jan-0001MOH | National Medical Research Council (NMRC) NMRC/OFLCG/002-2018
6 · The paper itself

Abstract

introductionSpread through air spaces (STAS) is an adverse histologic feature in early-stage lung adenocarcinoma (LUAD) incorporated into the ninth edition TNM staging. Despite its clinical significance, the molecular features underlying STAS in stage 1 LUAD remain incompletely characterised.

methodsPatients with stage 1 LUAD and known STAS status were identified. Whole exome and RNA sequencing were performed on tumour samples with matched normal controls. Disease-free survival (DFS) was analysed using the Kaplan-Meier method and Cox regression.

resultsAmong 378 patients, 54.2% had STAS+ tumours, with similar incidence between EGFR-mutant and EGFR-wildtype LUAD. STAS+ tumours were significantly associated with stage 1B disease, lymphovascular invasion, higher histological grade, micropapillary or solid predominant adenocarcinoma subtype and PD-L1 tumour proportion score ≥1%. STAS+ remained independently associated with inferior DFS after multivariable adjustment (hazard ratio 2.32, 95% CI 1.16-4.63; p = 0.017). At the molecular level, STAS+ tumours were enriched for TP53 co-mutations, whole genome doubling, non-TRU transcriptomic subtypes and upregulation of cell cycle-related pathways, with directionally consistent findings across EGFR-mutant and EGFR-wildtype tumours.

conclusionsSTAS+ in stage 1 LUAD is associated with a distinct molecular phenotype characterised by genomic instability and cell cycle dysregulation, consistent with a more aggressive biological phenotype with implications for risk stratification and adjuvant therapy selection.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.